38 citations
,
September 1996 in “Annals of Clinical Psychiatry” This review discusses the association between mood stabilizers and alopecia, providing diagnosis insights and management options, but reports no new clinical results.
47 citations
,
January 2003 in “American Journal of Clinical Dermatology” This article discusses the potential for severe adverse cutaneous drug reactions with mood-stabilizing agents, emphasizing the importance of monitoring and patient communication, but reports no new clinical findings.
April 2025 in “European Psychiatry” This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.
65 citations
,
July 2013 in “International Clinical Psychopharmacology” This review provides an overview of the prevalence and management of side effects of mood-stabilizing drugs in bipolar disorder patients and reports no new clinical results.
1 citations
,
July 2014 in “Current psychiatry” This review discusses the guidelines for using and monitoring mood stabilizers in bipolar disorders, highlighting that only a minority of patients receive guideline-adherent monitoring.